Holen Sie sich die Stockscreener-App
18.88
1.62%
-0.31
Schlusskurs vom Vortag:
$19.19
Offen:
$19.15
24-Stunden-Volumen:
2.27M
Relative Volume:
0.89
Marktkapitalisierung:
$2.41B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-9.3465
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
+4.19%
1M Leistung:
-14.38%
6M Leistung:
+41.32%
1J Leistung:
+63.32%
1-Tages-Spanne:
$18.77
$19.89
1-Wochen-Bereich:
$17.88
$19.89
52-Wochen-Spanne:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
18.88 | 2.45B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
180.31 | 30.01B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
58.37 | 10.67B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
41.06 | 7.36B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
78.89 | 6.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
25.07 | 4.93B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Is 10x Genomics Inc. still a buy after recent gains2025 Biggest Moves & AI Forecast Swing Trade Picks - mfd.ru
10x Genomics revenue up 1% to USD 166M in Q4 2025 - Medical Buyer
Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | 10x Genomics(TXG.US) Q4 2025 Earnings Conference - 富途牛牛
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com UK
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India
10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat
10x Genomics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey
10x Genomics Q4 Earnings Call Highlights - MarketBeat
10x Genomics, Inc. SEC 10-K Report - TradingView
10x Genomics: Fourth Quarter Financial Overview - Bitget
10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus
Can 10x Genomics Inc. stock outperform in a bear market2025 Top Decliners & High Return Trade Opportunity Guides - mfd.ru
10x Genomics (TXG) Q4 2025 Earnings Transcript - AOL.com
10x Genomics (TXG) Surpasses Q4 Revenue Expectations - GuruFocus
Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast - Investing.com
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 - Finviz
10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
10x Genomics Q4 2025 Financial Results: Loss Narrows, Revenue at $166MNews and Statistics - IndexBox
10x Genomics Q4 Loss Narrows, Revenue Rises; 2026 Guidance Set - marketscreener.com
10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
10x Genomics: Q4 Earnings Snapshot - kare11.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q4 Revenue $166.0M, vs. FactSet Est of $159.7M - marketscreener.com
10x Genomics Earnings Report: Q4 Overview - Benzinga
10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth - Stock Titan
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 - Finansavisen
10X Genomics faces earnings test as new pricing strategy debuts By Investing.com - Investing.com South Africa
10X Genomics faces earnings test as new pricing strategy debuts - Investing.com
10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations Amid ... By GuruFocus - Investing.com Canada
What makes 10x Genomics Inc. stock attractive todayQuarterly Profit Report & Free Community Consensus Stock Picks - mfd.ru
10x Genomics Earnings Preview - Sahm
10x Genomics Earnings Preview: Revenue Forecast, Analyst Estimates & Stock OutlookNews and Statistics - IndexBox
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - Finviz
10x Genomics, Inc. (TXG) Stock Analysis: Navigating Market Challenges with Cutting-Edge Genomics Technology - DirectorsTalk Interviews
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.63%
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):